Revive Therapeutics Ltd.


Company Logo

Company Overview

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. 

Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. 

Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Revive's Psilocybin Pharma division is led by Derrick Welsh.

Financial Highlights


Revenue (ttm)


Gross Profit (ttm)


Diluted EPS (ttm)

Management Team

Mr. Michael Frank
Chairman & CEO

Mr. Carmelo Marrelli ACIS, B.Comm., CA, CGA, CPA
Chief Financial Officer

Dr. Kelly T. McKee Jr., M.D., M.P.H.
Chief Scientific Officer Consultant

Dr. Onesmo Mpanju Ph.D.
Chief Regulatory Affairs Consultant

Mr. Derrick Alexander Welsh
COO of Psilocin Pharma

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile




Key Highlights

Market Capitalization

Shares Outstanding

Shares Short (% of Float)

Insider Ownership